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Instead of exploiting the differences between normal and cancer cells, seemingly unrelated anticancer modalities (from
immunotherapy to hormones) exploit (a) the differences between various normal tissues and (b) tissue-specific similarities of normal
and cancer cells. Although these therapies are successfully used for years to treat leukaemia and cancer, their unifying principles have
never been explicitly formulated: namely, they are aimed at differentiated cells and normal tissues and target both normal and cancer
cells in a tissue-specific manner. Whereas tiny differences between cancer and normal cells have yet to be successfully exploited for
selective anticancer therapy, numerous tissue-specific differences (e.g. differences between melanocytes, prostate, thyroid and breast
cells) provide a means to attack selectively that exact tissue that produced cancer. Despite inherent limitations, such as fostering
resistance and dedifferentiation, tissue-selective therapy have enormous potentials to control cancer.
British Journal of Cancer (2003) 89, 1147–1151. doi:10.1038/sj.bjc.6601256 www.bjcancer.com
& 2003 Cancer Research UK
Keywords: cancer; tissue; therapy; immunotherapy; hormones; resistance
                                  
As Robert Weinberg accurately pointed out, ‘virtually all the
proteins made by cancer cells are normal proteins’ (Dickey, 2002).
What is then a basis for immunotherapy of cancer? How
immunotherapy can possibly work, if cancer cells do not provide
a cancer-specific protein. What are these mysterious tumour-
specific antigens? The answer is startling. For example, the
melanoma-derived protein (a target of anticancer immunotherapy)
turned out to be a normal (melanocyte-differentiation) antigen
(Wang et al, 1996). So, it is not a cancer-specific protein, which is
absent in normal cells, but a tissue-specific protein that is shared
by both normal and malignant melanocytes. Even further,
malignant melanocytes tend to lose tissue-specific proteins
(dedifferentiation) rather than to acquire them. Many tumour
antigens are normal tissue-differentiation antigens (Overwijk et al,
1999; Overwijk and Restifo, 2000). Consequently, immunisation
with these ‘self’ antigens could induce autoimmunity. Vaccine
strategies targeting tissue differentiation antigens may be valuable
in cancers arising from nonessential cells and organs such as
melanocytes, prostate, testis, breast, and ovary (Overwijk and
Restifo, 2000). Thus, ‘anticancer’ immunotherapy is directed
against normal differentiation antigens.
Yet, it is more difficult to control the immune response than to
administer small molecular therapeutics. Can therapeutic agents
be designed in a tissue-specific fashion, to attack normal
differentiated cells? And is tissue-specific therapy applicable not
only to ‘non-essential’ tissues such as breast and prostate but also
to vital tissues such as lymphoid and thyroid. A therapy that is
aimed at ‘something’ unique for a particular tissue (Figure 1). It
may be a unique cellular biochemical activity (production of
melanin or uptake of iodine). It may be an antigen or an enzyme.
Or cell dependence on hormonesy . For example, normal prostate
epithelial and testicular cells selectively depend on androgens for
survival and proliferation.
HORMONAL THERAPY IN PROSTATE CANCER
Normal prostate epithelial cells depend on androgens for their
growth and survival. For example, androgen ablation induces
apoptosis of prostatic glandular cells. In 1941, it was discovered
that the initial growth of prostate cancer is dependent on
androgens. Androgen suppression (in the form of medical or
surgical castration with inhibition of adrenal androgens) became
the standard primary treatment for advanced prostate cancer.
Antiandrogen therapy causes regression of prostate tumours in
more than 80% of patients with metastatic disease (Reese, 2000).
During the course of prostate cancer progression, however, cells
convert from an androgen-dependent to an androgen-independent
(Craft et al, 1999; Feldman and Feldman, 2001). Following
androgen suppression, recurrent prostate carcinomas are able to
avoid apoptosis (Koivisto et al, 1997). Prostate cancer cells can
acquire the ability to grow without androgens by suppressing the
apoptotic machinery or by using growth factors and steroids other
than androgens (Feldman and Feldman, 2001). Following anti-
androgen therapy, almost half patients experienced a second
relapse heralded by a rise in the serum prostate-specific antigen
(PSA). Tumour progression on hormonal therapy is a surrogate for
impending cancer patient death (Zietman et al, 1996). Once a
relapse occurs following primary endocrine treatment, metastatic
prostate cancer is one of the most therapy-resistant human
neoplasms (Zietman et al, 1996).
In summary, antihormone therapy has an excellent response
(80%) but, on the other hand, promotes hormone-independent
disease, which is aggressive and resistant. By killing cancer cells
having a tissue-specific characteristic (e.g. hormone-dependence),
tissue-selective therapy causes remission but also selects for
resistant cancer (Figure 2). Received 16 April 2003; revised 25 June 2003; accepted 8 July 2003
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Loss of one tissue-specific trait (e.g. hormone-dependence) is not
necessarily associated with loss of other traits (e.g. expression of
PSA, a normal prostate-specific protease). Therefore, PSA is an
attractive target of tissue-specific therapy. For example, a peptide-
doxorubicin ‘prodrug’, which is cleaved and activated by PSA,
selectively kills prostate tumour cells in vivo (DeFeo-Jones et al,
2000).
ANTIHORMONAL THERAPY IN BREAST CANCER
The breast is a target organ for oestrogens and progesterone,
which control several functions of the normal and abnormal
mammary epithelium. As demonstrated by postmenopausal
hormone replacement therapy, oestrogens plus progestines induce
proliferation of breast epithelial cells localised to the terminal
duct-lobular unit of the breast, which is the site of development of
most breast cancers (Hofseth et al, 1999). Treatment with
antioestrogens (e.g. tamoxifen) is the first-line therapy of
oestrogen receptor (ER)-positive cancer, both for metastatic
disease and after mastectomy. Two-thirds of the patients with
metastatic breast cancers respond to tamoxifen (or toremifen) with
positive tumour regression for an average of 12–18 months.
Another 20% have prolonged stable disease lasting for at least 6
months. Patients who benefited most were postmenopausal and
had tumours strongly positive for both ER and progesterone
receptor (Osborne et al, 2000). In adjuvant therapy after surgical
treatment of nonmetastatic cancer, there was 50% reduction of the
odds of recurrence of breast cancer.
Like other tissue-selective therapies, antioestrogens (e.g. tamox-
ifen) are remarkably nontoxic. Therapeutic plasma concentrations
of tamoxifen are dozens times less than its maximally achievable
concentrations, which is 3–8mM (Bergan et al, 1999). Despite the
initial benefits of tamoxifen, most patients eventually relapsed
(Figure 2). Furthermore, such tamoxifen-resistant tumours may be
stimulated by tamoxifen and, in contrast, suppressed by oestro-
gens (Song et al, 2001). This potentially might be exploited for
‘withdrawal’ therapy in breast cancer. Similarly, in prostate cancer,
intermittent androgen blockade appears to be a potential
alternative to permanent androgen blockade (Wolff and Tunn,
2000).
GLUCOCORTICOID IN LEUKAEMIA
Glucocorticoids and synthetic steroids (dexamethasone, predniso-
lone) suppress functions, prevent proliferation, and induce
apoptosis in both T and B lymphocytes. Even during physiological
stress, glucorticoids can kill CD4(þ) and CD8(þ) thymocytes
(Ashwell et al, 2000). In addition to T lymphocytes, glucocorticoids
induce apoptosis in B cells, pre-B and immature B cells, which is
inhibited by Bcl-2 (Merino et al, 1994). Bcl-2 is highly expressed in
B-cell precursors (pro-B cells) and mature B cells, but is low at the
pre-B and immature B-cell stages of development (Merino et al,
1994). High levels of Bcl-2 and Bcl-x render intestinal intraepithe-
lial lymphocytes resistant to apoptosis by glucocorticoids (Van
Houten et al, 1997). Glucocorticoids-induced-apoptosis in cells of
the lymphoid lineage at certain stages of differentiation has been
exploited to a great extent in the therapy of malignant
lymphoproliferative disorders. For example, glucocorticoids are
included in almost all treatment regimens for childhood acute
lymphoblastic leukaemia (ALL). Leukaemic blast sensitivity to
glucocorticoids correlates with sensitivity to chemotherapeutic
agents and with outcome after multiagent therapy (Kaspers et al,
1998).
Effect of glucocorticoid therapy is, however, hampered by the
occurrence of resistant clones evolving under selective glucocorti-
coid pressure. At relapse, loss of sensitivity to glucocorticosteroids
is common and out of proportion to the loss of sensitivity to other
agents. Mechanisms of glucocorticoid resistance involve down-
regulation of glucocorticoid receptor, mutant receptor, abnormal
HSPs expression, and inactivation of apoptotic pathways (Tissing
et al, 2003).
We can generalise that tissue-selective therapy inevitably selects
for resistance (Figure 2). Another lesson of glucocorticoid therapy
is that tissue-selective therapy may target vitally important tissues,
namely, the lymphoid system, without dose-limiting side effects.
Of course, immunosuppression is an unavoidable side effect. Also,
glucocorticoids cause nonlymphoid side effects, which, in theory,
can be avoided by substituting glucocorticoids with antilympho-
cyte antibodies. Antibodies can deliver toxins and radioactivity
(Allen, 2002; Frankel, 2002).
We suggest that, in essential tissues (e.g. the immune
system), side effects could be further decreased by targeting
cell subpopulation that originated a malignant clone (a subtissue-
selective therapy). Immunotherapy of leukaemia provides
examples.
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Figure 1 Tissue-selective and standard anticancer therapies. Standard
therapy that preferentially targets proliferating cells causes side effects by
targeting an essential tissue (tissue 2). Tissue-selective therapy targets
cancer cells (Ca) and sub population of normal cells of the same tissue, with
low side effects.
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Figure 2 Tissue-selective therapy: from remission to relapse. By killing
cells with tissue-specific targets (or traits such as hormone-dependence),
tissue-selective therapy causes clinical response (remission). Cancer cells
lacking tissue-specific targets survive, leading to relapse. Once relapsed,
cancer is likely to be resistant to this therapy.
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Antibody-based therapy is intended to target leukaemia cells
selectively. In reality, it targets tissue-specific antigens. Several
dozens of surface antigens, referred to as CDs, are expressed on
normal lymphoid and myeloid cells. Two monoclonal antibodies,
rituximab (anti-CD20) and Campath-1H (anti-CD52), are widely
used. Rituximab is active in follicular non-Hodgkin’s lymphomas
and in chronic lymphocytic leukaemia (CLL) with response rates
of 50%. It suppresses B cells without affecting T cells. Anti-CD52
antibody has notable side effects, consistent with their action
against both B and T cells (Countouriotis et al, 2002).
TISSUE-SELECTIVE IMMUNOTHERAPY IN
MELANOMA
Like other melanoma differentiation antigens, tyrosinase-related
proteins, TRP-1 and TRP-2, are expressed in melanoma, melano-
cytes, and retina (Wang et al, 1996). The immune responses to
TRP-1 caused melanocyte destruction with depigmentation
(vitiligo). The immune response against TRP-1 (anti-TRP-1
antibodies) could destroy both normal and malignant melanocytes
(Overwijk and Restifo, 2000). The transfer, to patients with
metastatic melanoma, of selected tumour-reactive T cells directed
against overexpressed self-derived differentiation antigens led to
regression of metastatic melanoma as well as to the onset of
autoimmune melanocyte destruction (Dudley et al, 2002).
Melanomas tend to become less pigmented in the course of
malignant progression. Antimelanocyte therapy will likely facilitate
this progression.
EXPLOITING MELANIN BIOSYNTHESIS IN
MELANOMA
Unique tyrosine metabolic pathways in normal melanocytes can be
exploited for selective killing of melanocytes, because melanogen-
esis is inherently toxic and uniquely expressed in melanocytic
cells. Sulphur-containing substrate (tyrosine) analogues show
selective cytotoxicity towards melanoma cell lines (Thomas et al,
1999). Nitrosoureas-containing tyrosine derivatives are evaluated
as potential antimelanoma agents (Gadjeva, 2002). Effective
melanocyte-toxic therapies must cause vitiligo. This side effect is
a marker of therapeutic activity.
THYROID CANCER: ANTIHORMONE THERAPY AND
RADIOACTIVE IODINE
The thyrotropin (TSH) hormone regulates proliferation and
thyroid-specific gene expression (differentiation) of thyroid follicle
cells. Early thyroid tumour development is correlated with
mutation of alternative genes, including Ras and the TSH receptor
(Wynford-Thomas, 1997). Thyrotropin suppression therapy (thyr-
oxine application) of differentiated thyroid cancer is supported by
most clinical studies (Pujol et al, 1996). In one-third of the cases
following TSH-suppression therapy (and radioiodine therapy),
dedifferentiation is observed, giving rise to tumours that are
refractory to conventional treatment (Figure 2). Eventually, this
may lead to the most malignant human tumour (anaplastic thyroid
carcinoma) with a life expectancy of only a few months.
Although p53 mutations are present almost exclusively in
poorly differentiated thyroid tumours (Wynford-Thomas,
1997), p53 mutation alone is not sufficient to drive progression
of thyroid cancer to the aggressive anaplastic form (Wyllie et al,
1999).
Thyroid cancers are classified as papillary (82%), follicular (8%),
medullary (9%), and anaplastic (1%). Anaplastic thyroid cancer
cells are characterised by the absence of expression of thyroid-
specific genes (TSH receptor, thyroglobulin, and thyroperoxidase).
This results in their inability to incorporate radiactive iodine.
Uptake of radioactive iodine, a normal function of thyroid cells,
allows its accumulation 2000 over serum levels, thus killing the
thyroid cell selectively. The prognosis of patients with papillary,
the most differentiated thyroid cancer, is favourable and depends
on tumour differentiation and the ability to take up radioactive
iodine. The overall cure rate of radioiodine therapy (after 12 years)
is 50% (papillary 65% vs follicular 23%) (Pelikan et al, 1997).
Lacking thyroid-specific functions dedifferentiated tumours are
inaccessible to standard therapeutic procedures such as radio-
iodide therapy and thyrotropin suppression.
We can conclude that tissue-selective therapy (anti-TSH and
radioactive iodine) is very effective in differentiated cancers but
can select for undifferentiated cancer cells (Figure 2). Therefore, it
is feasible to alternate tissue-selective and differentiating therapies
(Figure 3).
COMPLEMENTARY THERAPIES: DIFFERENTIATING
AND TISSUE-SELECTIVE THERAPY
Retinoic acid (RA) causes partial redifferentiation and increases
iodine uptake in thyroid carcinoma cell lines. In clinical studies,
about 40% of the patients responded to RA with an increased
radioiodide uptake (Schmutzler and Koehrle, 2000; Schmutzler,
2001). Also, histone deacetylase (HDAC) inhibitor, FR901228, can
modulate the expression of thyroid-specific genes. In follicular and
aplastic thyroid cancer cell lines, a low concentration of FR901228
(1ngml
 1) increased both thyroglobulin, the transporter for
iodine and radioiodine accumulation (Kitazono et al, 2001).
FR901228 was suggested to be used clinically in thyroid
carcinomas that are unable to trap iodine as an adjunct to
radioiodine therapy (Kitazono et al, 2001). In an anaplastic cell
line, doxorubicin, a DNA-damaging drug, induced morphologi-
cally differentiated phenotype (Blagosklonny et al, 1998). It has
been reported a conversion of non-iodine-concentrating thyroid
carcinoma metastasis into iodine-concentrating foci after che-
motherapy. A patient with metastatic papillary carcinoma was
treated with cisplatin and doxorubicin. Repeat
131I imaging after
three cycles of chemotherapy showed significant
131I uptake in
previously non-iodine-concentrating lesions (Morris et al, 1997).
Suppression of TSH and radioiodine are highly effective in
differentiated thyroid cancer. On the other hand, they eventually
select for undifferentiated cancer, insensitive to tissue-selective
therapy. Differentiating therapies (RA, HDAC inhibitors, doxor-
Differentiated
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cancer
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Differentiating
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Figure 3 Alternating tissue-selective and differentiating therapies. Tissue-
selective and differentiating therapies complement each other. Tissue-
selective therapy kills differentiated cancer cells (cells having tissue-specific
traits) but may promote undifferentiated cancer, which is insensitive to
tissue-selective therapy. Then, differentiating therapy is needed. By
reactivating tissue-specific genes, differentiating therapies may permit a
new cycle of tissue-specific therapy.
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tissue-specific genes, differentiating therapy permits a new round
of tissue-specific therapy (Figure 3). Tissue-selective and differ-
entiating therapies complement each other (Figure 3).
PERSPECTIVES OF TISSUE-SELECTIVE THERAPY
Standard therapy of cancer is limited by its toxicity to normal cells
(side effects). Logically, the goal of anticancer drug development is
to exploit the differences between normal and cancer cells. Both
hormonal therapy and immunotherapy were, historically, intended
to target cancer cells. It is believed that ‘the goal of monoclonal
antibody therapy is to target specific cell surface antigens on
malignant hematopoietic cells, while sparing normal cells and
tissues’ (Countouriotis et al, 2002). In reality, tissue-specific
therapy will preferentially spare leukaemia cells, given their
tendency towards dedifferentiation. For example, a number of
CD20 receptors (one of the targets of immunotherapy) is 10 times
lower on leukaemic cells than on normal B cells (Rossmann et al,
2001).
Tissue-selective therapy exploits peculiarities of normal tissues:
incorporation of iodine by thyroid tissue, dependence on
androgens by prostate tissue, expression of CD20 by lymphocytes,
just to name a few. Potentials in the development of antitissue
therapies are enormous, because differences between tissues are
diverse and profound. A breast cell can produce milk, for instance,
whereas a gastric cell is capable to secrete a gastric acid. These
different biochemical pathways can be, in principle, targeted
pharmacologically, by prodrugs, for instance. Research in bio-
chemistry of normal tissues, not cancer cells, is needed to facilitate
development of tissue-selective therapy.
By definition, tissue-selective therapy targets normal and cancer
cells of the same tissue, without affecting other tissues. Targeting
nonessential tissues results in few side effects. Even side effects of
tamoxifen in breast cancer patients are caused by tissue-
nonselectivity of tamoxifen (e.g. effects on brain and endome-
trium). Furthermore, therapies against essential tissues (e.g.
lymphocytes) are effective, even though they cause tissue-specific
side effects (e.g. immunosuppression). To decrease side effects,
novel therapy should target a subtissue instead of an entire tissue
(e.g. a subpopulation of lymphocytes).
Not side effects but development of resistance, which may be
accompanied by dedifferentiation, is an inherent limitation of
tissue-selective therapy (Figure 2). Once relapsed, such cancer is
resistant and aggressive. However, acquiring drug-resistance is a
hallmark of all selective and effective therapies, including Gleevec
for the therapy of CML and antibiotics for bacterial infections. This
is predictable (Blagosklonny, 2002). Similarly, by killing differ-
entiated cancer cells, which have tissue-specific traits, tissue-
selective therapy ‘causes’ dedifferentiation of cancer. Therefore,
tissue-selective therapy should be complemented with differentiat-
ing therapy (Figure 3) and other therapeutic approaches (e.g.
antiangiogenic and standard therapy). Then, by causing remis-
sions without severe side effects, tissue-selective therapy may
control cancer and even ‘cure’ cancer, given the limited human
lifespan.
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